Felipe José Silva Melo Cruz

Publications by Year

Research Areas

Cancer Immunotherapy and Biomarkers, Gastric Cancer Management and Outcomes, Prostate Cancer Treatment and Research, Radiopharmaceutical Chemistry and Applications, Breast Cancer Treatment Studies

Most-Cited Works

• → Darolutamide Plus Androgen-Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer by Disease Volume and Risk Subgroups in the Phase III ARASENS Trial(2023)200 cited
• → Darolutamide in Combination With Androgen-Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer From the Phase III ARANOTE Trial(2024)113 cited
• → Subcutaneous Versus Intravenous Amivantamab, Both in Combination With Lazertinib, in Refractory Epidermal Growth Factor Receptor–Mutated Non–Small Cell Lung Cancer: Primary Results From the Phase III PALOMA-3 Study(2024)98 cited
• → Preference for the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with HER2-positive early breast cancer (PHranceSCa): A randomised, open-label phase II study(2021)67 cited
• → Circulating free plasma tumor DNA in patients with advanced gastric cancer receiving systemic chemotherapy(2018)57 cited
• → Giredestrant for Estrogen Receptor–Positive, HER2-Negative, Previously Treated Advanced Breast Cancer: Results From the Randomized, Phase II acelERA Breast Cancer Study(2024)54 cited
• → Enzalutamide plus radium-223 in metastatic castration-resistant prostate cancer: results of the EORTC 1333/PEACE-3 trial(2025)28 cited
• → Tumor infiltrating lymphocytes after neoadjuvant IRX-2 immunotherapy in oral squamous cell carcinoma: Interim findings from the INSPIRE trial(2020)20 cited
• → Increased circulating tumor DNA as a noninvasive biomarker of early treatment response in patients with metastatic ovarian carcinoma: A pilot study(2020)15 cited
• → Hormone receptor-negative as a predictive factor for pathologic complete response to neoadjuvant therapy in breast cancer(2019)11 cited